Oxford’s Doug Altman Receives Lifetime Achievement Award
Altman has been instrumental in the development of “truly robust guidelines for the reporting of clinical trials and wider clinical research studies”.
Prof. Doug Altman, founding director of the Centre for Statistics in Medicine in Oxford, U.K. has received the 2015 BMJ Lifetime Achievement for his contribution to improving reporting of health research.
Altman has been instrumental in the development of “truly robust guidelines for the reporting of clinical trials and wider clinical research studies,” noted GSK’s Global Head of Epidemiology Dr. Andrew Roddam, who presented the award on behalf of the sponsors.
Dr Fiona Godlee, Editor-in-chief of the The BMJ, said Professor Altman “has done more than anyone else to encourage researchers to fully report what they actually did, warts and all, rather than letting the best be the enemy of the good or, worse, pretending that research is perfect.”
Click here for the full release about the BMJ award winners.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
